Effects of S-0509, a novel CCK(B)/gastrin receptor antagonist, on acid secretion and experimental duodenal ulcers in rats

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 1, 1999, Pages 87-96

  Takeuchi, Koji ^a   Hirata, T ^a   Yamamoto, H ^a   Kunikata, T ^a   Ishikawa, M ^b   Ishihara, Y ^b  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 2 [(TERT BUTOXYCARBONYLMETHYL)[(3 CARBOXYPHENYL)UREIDOMETHYLCARBONYL]]AMINOBENZOPHENONE; BENZOPHENONE DERIVATIVE; CARBACHOL; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; EPIRIZOLE; HISTAMINE; PENTAGASTRIN; PEPTONE; S 0509; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DUODENUM ULCER; INTRADUODENAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; STOMACH ACID SECRETION; ULCER HEALING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZODIAZEPINONES; BENZOPHENONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENAL ULCER; EPIRIZOLE; GASTRIC ACID; GASTRIC MUCOSA; HYDROGEN-ION CONCENTRATION; MALE; PENTAGASTRIN; PEPTONES; PHENYLUREA COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLECYSTOKININ;

EID: 0032939488     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00439.x     Document Type: Article

References (35)

1. 2-antagonist withdrawal - a comparative study with nizatidine, ranitidine and famotidine. Aliment Pharmacol Ther 1991; 5: 391-8.
2. 2 Larsson H, Carlsson E, Ryberg B, Fryklund J, Wallmark B. Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am J Physiol 1988; 254: G33-G39.
3. 2 receptor blockade. Gut 1991; 32: 1455-60.
4. 4 Larsson H, Carlsson E, Mattsson H, et al. Plasma gastrin and gastric enterochromaffin-like cell activation and proliferation: studies with omeprazole and ranitidine in intact and antrectmized rats. Gastroenterology 1986; 90: 391-9.
5. 5 Larsson H, Carlsson E, Hakanson R, et al. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion: Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1988; 95: 1477-86.
6. 6 Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C. Toxicological studies on omeprazole. Scand J Gastroenterol 1985; 20(Suppl. 108): 53-69.
7. 7 Berlin RG. Omeprazole: gastrin and gastric endocrine cell data from clinical studies. Dig Dis Sci 1991; 56: 129-36.
8. 8 Brunner G, Lamberts R, Creutzfeld W. Efficacy and safety of omeprazole in the long-term treatment of peptic ulcer and reflux oesophagitis resistant to ranitidine. Digestion 1990; 47(Suppl. 1): 64-68.
9. 2 blockade and gastric carcinoid tumors in the rat. Gut 1985; 26: 1284-95.
10. 10 Hakanson R, Larsson LI, Liedberg G, Sundler H. Gastrin and the trophic control of gastric mucosa. Scand J Gastroentrol 1996; 21(Suppl. 118): 18-30.
11. 11 Lotti VJ, Chang RSL. A new potent, selective non-peptide gastrin antagonist, and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 1989; 162: 273-80.
12. 12 Nishida A, Miyata K. Tsutsumi R, et al. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzo-diazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1994; 269: 725-31.
13. 13 Varga G, Campbell DR, Bussjaeger LJ. Role of gastrin and cholecystokinin receptors in regulation of peptone-stimulated acid secretion in conscious rats. Eur J Pharmacol 1993; 250: 37-42.
14. 14 Nishida A, Takinami Y, Yuki H, Kobayashi A, et al. YM022 {(R)-1-[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea}, a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. J Pharmacol Exp Ther 1994; 270: 1256-1261.
15. 15 Eissele R, Patberg H, Koop H, et al. Effect of gastrin receptor blockade on endocrine cells in rats during achlorhydria. Gastroenterology 1992; 103: 1596-601.
16. 16 Nishida A, Kobayashi-Uchida A, Akuzawa S, et al. Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression. Am J Physiol 1995; 269: G699-G705.
17. 17 Hagishita S, Murakami Y, Seno K, et al. Synthesis and pharmacological properties of ureidomethylcarbamoylphenylke-tone derivatives. A new potent and subtype-selective nonpeptide CCK-B/gastrin receptor antagonist, S-0509. Bioorg Med Chem Lett 1997; 5: 1695-714.
18. 18 Takeuchi K, Furukawa O, Tanaka H, Okabe S. A new model of duodenal ulcers induced in rats by indomethacin plus histamine. Gastroenterology 1986; 90: 636-45.
19. G-nitro-L-arginine methyl ester on duodenal alkaline secretory and ulcerogenic responses induced by mepirizole in rats. Dig Dis Sci 1995; 40: 670-7.
20. 20 Okabe S, Ishihara Y, Inoo H, Tanaka H. Mepirizole-induced ulcers in rats and their pathogenesis. Dig Dis Sci 1982; 27: 242-9.
21. B/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat. Br J Pharmacol 1991; 104: 973-7.
22. 22 Chen IW, Dorley JM, Ramjit HG, Pitzenberger SM, Lin M. Physiological disposition and metabolism of L-365,260, a new potent antagonist of brain cholecystokinin receptor, in laboratory animals. Drug Metab Dispos 1992; 20: 390-5.
23. 23 Van de Brug FJ, Jansen JB, Kuijpers RJ, Lamers CB. Inhibition of meal-stimulated gastric acid secretion by gastrin immunoneutralization in rats. Eur J Pharmacol 1992; 198: 197-201.
24. 24 Lloyd KC, Raybould HE, Tache Y, Walsh JH. Role of gastrin, histamine, and acetylcholine in the gastric phase of acid secretion in anesthetized rats. Am J Physiol 1992; 262: G747-G755.
25. 25 Tanaka H, Ueki S, Ohno T, Takeuchi K, Okabe S. Pathogenic mechanisms involved in mepirizole-induced duodenal damage in the rat. Jpn J Phannacol 1986; 42: 383-96.
26. 26 Tanaka H, Takeuchi K, Okabe S. Role of accumulated gastric content in the pathogenesis of cysteamine-and mepirizole-induced duodenal ulcers in the rat. J Int Med 1990; 228: S69-S75.
27. 27 Ueshima K, Takeuchi K, Ohuchi T, Okabe S. Acid secretory and duodenal ulcerogenic responses induced by mepirizole in anesthetetized rats; relation to body temperature. Dig Dis Sci 1994; 39: 1625-32.
28. 28 Yang H. Wong H. Walsh JH, Tache Y. Effect of gastrin monoclonal antibody 28.2 on acid response to chemical vagal stimulation in rats. Life Sci 1989; 45: 2413-18.
29. 29 Lichtenberger LM, Szabo S, Trier JS. Duodenal ulcerogens, cysteamine and propionitrile, stimulate serum gastrin levels in the rat. Gastroenterology 1977; 73: 1305-8.
30. 30 Okabe S, Takeuchi K, Nakamura K, Takagi K. Effect of antipeptic and anticholinergic agents on the development and healing of duodenal ulcers in the rat. Digestion 1974; 10: 113-21.
31. 31 Okabe S, Takeuchi K, Urushidani T, Murata T, Takagi K. Effects of cimetidine on healing of chronic gastric and duodenal ulcers in dogs. Am J Dig Dis 1978; 23: 166-8.
32. 32 Takeuchi K, Johnson LR. Effect of cell proliferation on healing of gastric and duodenal ulcers in rats. Digestion 1986; 33: 92-100.
33. 33 Konturek SJ. Brzozowski T. Dembinski A, Warzecha Z, Konturek PK, Yanaihara N. Interaction of growth hormone releasing factor and somatostatin on healing and mucosal growth in rats: Role of gastrin and epidermal growth factor. Digestion 1988; 41: 121-8.
34. 34 Inauen W, Wyss PA, Kayser S. Influence of prostaglandins, omeprazole, and indomethacin on healing of experimental gastric ulcers in the rat. Gastroenterology 1988; 95; 636-41.
35. 35 Okabe S, Tsukimi Y. Does omeprazole-induced hypergastrinemia contribute to the enhanced healing of acetic acid-induced gastric ulcers in rats? Inflammopharmcol 1996; 4: 267-77.